Research Study Summary
Alzheimers? Be a Part of Research.
This study is for participants that have been diagnosed with a mild to moderate form of Alzheimer's disease (AD). This research involves an experimental study drug known as LY2062430. The primary objective of this study is to test whether LY2062430 will slow the rate of mental (thinking and remembering) decline of Alzheimer's disease as compared with placebo (a substance that looks like the study drug, but has no medicine).
Qualified Participants Must: Be diagnosed with a mild to moderate form of Alzheimer's disease; Have a reliable caregiver who is in frequent contact with you; Have good veins
Qualified Participants Will Receive: $50 per completed study visit.
To Learn more
CW ID: 157013
Date Last Changed:
July 24, 2013
Clinical Trial Snapshot
- Both Male and Female
- Overall Status
- Facility Type
- $50 and up
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.